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We investigated the eﬀects of apocynin on high-fat diet- (HFD-) induced insulin resistance in C57BL/6 mice. After 12 weeks
of HFD, the mice that exhibited insulin resistance then received 5 weeks of apocynin (2.4g/L, in water). Following apocynin
treatment, fasting glucose, insulin, and glucose tolerance test showed signiﬁcant improvement in insulin sensitivity in HFD-fed
mice. We demonstrated that serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and leptin were remarkably
reduced with apocynin treatment. We also found that mRNA expression of TNF-α, IL-6, and monocyte chemoattractant protein-1
(MCP-1) in the liver and mRNA expression of TNF-α, IL-6, MCP-1, and leptin in adipose tissue were suppressed by apocynin.
Furthermore, the activity of transcription factor NF-κB in the liver was signiﬁcantly suppressed with apocynin treatment. These
results suggest that apocynin may reduce inﬂammatory factors in the blood, liver, and adipose tissue, resulting in amelioration of
insulin resistance in HFD-fed mice.
1.Introduction
Insulin resistance is one of the critical mechanisms of
the type 2 diabetes [1]. Increasing evidence suggests that
inﬂammation plays an important role in the development
of insulin resistance [2]. The inﬂammatory status of the
liver and adipose tissue, the main insulin-resistance-related
organs, is critical for insulin sensitivity of the whole body
[3, 4].
During development of inﬂammation in the liver, hep-
atocytes are exposed to the increasing cytokines such as
tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and
monocyte chemoattractant protein-1 (MCP-1) [5]. These
cytokines were regulated by nuclear factor kappa-B (NF-κB)
[6, 7]. A number of studies demonstrated that hepatic NF-
κB activation was linked to the development of the whole
body inﬂammation, resulting in insulin resistance [8, 9].
Additionally, adipose tissue is an active endocrine organ
that secretes numerous inﬂammation-related adipokines,
cytokines, and chemokines. The expression of TNF-α,I L -
6, MCP-1, and leptin is upregulated in the adipose tissue of
obese mice which is closely associated with insulin resistance
[10–12].
Interestingly, some studies reported that oxidative stress
could induce inﬂammation during development of insulin
resistance [13, 14]. Oxidative stress which is induced by
excess reactive oxygen species (ROS) could activate NF-κB
[15]. Antioxidants have been reported to potently suppress
the activation of NF-κB in the liver [16–18]. Furthermore,
increased oxidative stress in adipocytes causes dysregulation
of cytokines and adipokines, including adiponectin, MCP-1,
IL-6, and plasminogen activator inhibitor-1 (PAI-1) [19, 20].
Accordingly,antioxidantshavebeenalsoreportedtodecrease
inﬂammation in adipose tissue and ultimately ameliorate
insulin resistance [21, 22].
Apocynin (4-hydroxy-3-methoxy-acetophenone) is a
constituent of the Himalayan herb Picrorhiza kurrooa Royle
(Scrophulariaceae) which is regarded as an inhibitor of
nicotinamide adenine dinucleotide phosphate (NADPH)-
oxidase and is widely used as an antioxidant in research. In
addition, apocynin also exhibits anti-inﬂammatory eﬀects
in previous studies [23, 24]. It was demonstrated that2 Mediators of Inﬂammation
apocynin suppressed NF-κBi ns p o n t a n e o u s l yh y p e r t e n -
sive rats [25], downregulated TNF-α protein expression
in coronary arteries [26], decreased vascular cell adhesion
molecule-1(VCAM-1)inducedbyTNF-αinveinendothelial
cells [27], reduced polymorphonuclear granulocyte chemo-
taxis [28], inhibited peroxynitrite in airway lumen in mice
[29], attenuated inﬂammation-mediated cartilage destruc-
tion activity in human articular cartilage [30], and reduced
cyclooxygenase (COX)-2 expression in human monocytes
[31]. Since the critical role of inﬂammation in genesis
of insulin resistance, it is reasonable to speculate that
apocynincouldimproveinsulinresistancethroughsuppress-
ing inﬂammation. However, no studies were conducted to
examine the eﬀects of apocynin on inﬂammation and its
subsequent eﬀects on insulin resistance.
In this study, C57BL/6 mice were fed with high-fat diet
(HFD) to establish insulin resistance for investigating the
eﬀectsofapocyninontheexpressionofinﬂammatoryfactors
in blood, liver, and adipose tissue, and then evaluating the
improvement of insulin sensitivity with apocynin treatment.
2. Methods
2.1. Animals and Experimental Procedures. Four-week-old
male C57BL/6 mice used in this study were purchased from
animal center, Yangzhou University (Yangzhou, Jiangsu,
China).Themicewerefedeitherwithhigh-fatdiet(60%kcal
fat, 20% kcal carbohydrates, 20% kcal protein, Guangzhou
animal experiment center, Guangzhou, China), or with
normal chow diet (10% kcal fat, 70% kcal carbohydrates,
20% kcal protein) after one week’s acclimation period. Mice
were kept on a 12-hour light, 12-hour dark cycle and fed ad
libitum. After 12 weeks of feeding, the HFD-fed mice showed
obvious phenotypes of insulin resistance compared to the
normal diet control group (ND-Con). We then randomly
dividedthemintotwogroups(6micepergroup).Onegroup
received normal water (HFD control group, HFD-Con),
while the other group received apocynin (2.4g/L) dissolved
in drink water (apocynin group, HFD-Apo) for another
ﬁve weeks with HFD. Mice were sacriﬁced after fasting for
12 hours. After given ketamine-xylazine (130/8.8mg/kg),
their tissues were harvested, weighed, snap frozen in liquid
nitrogen, and stored at −80
◦C until use. Dietary intake and
body weight were recorded every week. All procedures were
approved by the Nanjing University’s Animal Care and Use
Committee.
2.2. Plasma Parameters. Mice were fasted for 12 hours,
and blood samples were collected from the orbital sinus
underanesthesia.Aftercentrifugationat15,000×gfor1min,
the supernatants of the blood samples were separated and
subjected to measurements of leptin, TNF-α, and IL-6 levels
with the ELISA kits (RayBiotech, Norcross, GA, USA).
Plasma insulin was determined with Mouse Insulin ELISA
Assay kit (Linco, Charles, MO, USA).
2.3. Intraperitoneal Glucose Tolerance Tests (IPGTTs). Mice
werefastedfor6hourspriortoIPGTTs.Glucosewasinjected
intraperitoneally with the concentration of 1g/kg body
weight. Blood glucose measurement were obtained from the
tail at 0, 30, 60, and 120min. Blood glucose levels were
determined at indicated intervals with One Touch Proﬁle
Glucose Meter (Johnson & Johnson, New Brunswick, NJ,
USA).
2.4. Quantitative PCR Analysis. Total RNA was extracted
fromtheliverandepididymaladiposetissueofmicebyTrizol
(TakaraBio,Shiga,Japan).SynthesisofcDNAwasperformed
by M-MLV reverse transcriptase (Toyobo, Osaka, Japan).
Quantitative real-time PCR was performed with SYBR
Premix Ex Taq (Takara Bio, Shiga, Japan), using the StepOne
Real-Time PCR system according to the manufacturer’s
instructions (Applied Biosystems, Foster City, CA, USA).
The primer pairs used in the present study are listed in
Table 1. Final results were normalized against β-actin gene
expression.
2.5. NF-κB Activity Assay. Nuclear protein extracts were
prepared from liver tissue with the nuclear extract kit
(ActiveMotif,Carlsbad,CA)accordingtothemanufacturer’s
instructions. Protein concentrations were then quantiﬁed
with a Bradford assay, and equal amounts of protein were
used in a colorimetric NF-κB assay speciﬁc for the activated
form of p65 subunit of NF-κB( T r a n sA MN F - κB p65 kit;
Active Motif, Carlsbad, CA).
2.6. Statistical Analysis. Data are expressed as the means
± SEM. P values were determined by one-way ANOVA
followed by LSD and diﬀerences were considered signiﬁcant
if P<. 05.
3. Results
3.1. Eﬀe c to fA p o c y n i no nG r o w t hP a r a m e t e r s .The eﬀect of
apocynin on body weight in HFD-fed mice was shown in
Figure 1(a). The body weight of HFD-Apo group and HFD-
Con group were similar (P>. 05) and signiﬁcantly higher
than that in the ND-Con group until 3 weeks after the
treatmentofapocynin(P<. 05).Fromthefourthweektothe
end of the experiment, the body weight of HFD-Apo group
wasclearlylowerthanthatofHFD-Congroup(P<. 05).The
mean dietary intake during the experiment was signiﬁcantly
lower in the HFD-Con and HFD-Apo groups than that in
the ND-Con group (P<. 05, Figure 1(b)), while energy
intake has no signiﬁcant diﬀerence among groups (P>. 05,
Figure 1(c)).
3.2. Eﬀect of Apocynin on Insulin Sensitivity, Fasting Glucose,
and Fasting Insulin. IPGTTs were performed before the
sacriﬁce of the mice to assess glucose tolerance (Figure 2(a)).
Area under the curve (AUC) parameter was employed
as the index of glucose tolerance (Figure 2(b)). AUC was
signiﬁcantly higher in the HFD-Con group compared to
the ND-Con group (P<. 05). The HFD-Apo group had
remarkably lower AUC than the HFD-Con group (P<. 05).
At the end of the IPGTTs, fasting glucose and fasting insulinMediators of Inﬂammation 3
Table 1: Primer pairs used in present study.
Gene Forward primer Reverse primer
TNF-α CAGGAGGGAGAACAGAAACTCCA CCTGGTTGGCTGCTTGCTT
IL-6 TCCAGTTGCCTTCTTGGGAC GTGTAATTAAGCCTCCGACTTG
MCP-1 CAATCAATGCCC CAGTCAC GATTCTTGGGTTGTGGGAGTG
Leptin GATGACACCAAAACCCTCATC GCCACCACCTCTG TGGAGTAG
Adiponectin GTCAGTGGATCTGACGACACCAA ATGCCTGCCATCCAACCTG
Actin CATCCGTAAAGACCTCTATGCCAAC ATGGAGCCACCGATCCACA
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Figure 1: Eﬀect of apocynin on body weight, food intake, and energy intake. C57BL/6 mice were fed with HFD for 12 weeks to induce
insulin resistance. After 12 weeks of feeding, the HFD-fed mice were divided into two groups. The HFD-fed mice in one group were treated
with apocynin (2.4g/L) in drink water (HFD-Apo, n = 6) for another 5 weeks HFD feeding; the HFD-fed mice in the other group were
employed as HFD controls (HFD-Con, n = 6). Normal control mice were fed a normal diet and untreated with apocynin (ND-Con, n = 6).
(a) Body weight of three groups. The body weight of the HFD-Apo group was lower than that of the HFD-Con group since the fourth week
afterapocynintreatment.(b)Foodintake.ThefoodintakeoftheHFD-ApogroupandHFD-CongroupwerelowerthanthatintheND-Con
group. (c) Energy intake. There are no diﬀerences among groups. #P<. 05 versus ND-Con group, ∗P<. 05 versus HFD-Con group.
levels were signiﬁcantly higher in HFD-Con group than ND-
Con group (P<. 05). Apocynin administration signiﬁcantly
improved fasting glucose (Figure 2(c)) and fasting insulin
in HFD-Apo group compared to the HFD-Con group
(Figure 2(d))( P<. 05, resp.)
3.3. Eﬀects of Apocynin on Systemic Inﬂammation. Serum
inﬂammatory cytokines levels are shown in Figures 3(a)–
3(c). The levels of TNF-α, IL-6, and leptin of HFD-Con
group were remarkably higher than ND-Con group (P<. 05,
resp.). Apocynin treatment signiﬁcantly decreased the levels4 Mediators of Inﬂammation
03 0 60 120
0
5
10
15
20
HFD-Con
HFD-Apo
ND-Con
Time (min)
G
l
u
c
o
s
e
(
g
/
d
L
)
(a)
HFD-Con HFD-Apo ND-Con
0
500
1000
1500
2000
2500
#
∗
A
r
e
a
u
n
d
e
r
t
h
e
c
u
r
v
e
(b)
HFD-Con HFD-Apo ND-Con
6
8
10
12
#
∗
F
a
s
t
i
n
g
g
l
u
c
o
s
e
(
g
/
d
L
)
(c)
#
∗
HFD-Con HFD-Apo ND-Con
0
2
4
6
8
10
F
a
s
t
i
n
g
i
n
s
u
l
i
n
(
n
g
/
m
L
)
(d)
Figure 2: Eﬀect of apocynin on obesity-induced glucose intolerance. (a) IPGTTs was performed by injection intraperitoneally of 1g/kg
glucose after 6-hour fasting, and blood samples were drawn from tail veins after 0, 30, 60, and 120 min. (b) Area under the curve was
measured as a parameter of insulin resistance. Signiﬁcant diﬀerence was detected between HFD-Apo group and HFD-Con group. (c) Fasting
glucose levels. There is a signiﬁcant diﬀerence between HFD-Apo group and HFD-Con group. (d) Fasting insulin levels. The fasting insulin
level of the HFD-Apo group is lower than that of HFD-Con group. #P<. 05 versus ND-Con group, ∗P<. 05 versus HFD-Con group.
of TNF-α,I L - 6 ,a n dl e p t i ni nt h es e r u m( P<. 05, resp.). We
then further tested inﬂammation related gene expression in
adipose tissue and liver.
3.4.EﬀectsofApocyninonInﬂammation-RelatedGeneExpres-
sion in Adipose Tissue. In adipose tissue, the HFD-Con
group exhibited signiﬁcantly higher gene expression of
TNF-α, IL-6, MCP-1, and leptin and lower expression of
adiponectin than ND-Con group (P<. 05, resp.). Apocynin
treatment obviously decreased TNF-α, IL-6, MCP-1, and
leptin expression (P<. 05, resp.) (Figures 4(a)–4(d)).
However, there was no change in expression of adiponectin
after treatment with apocynin (P>. 05) (Figure 4(e)).
3.5.EﬀectsofApocyninonInﬂammation-RelatedGeneExpres-
sion and NF-κBA c t i v i t yi nt h eL i v e r .In the liver, gene
expression TNF-α, IL-6, and MCP-1 were signiﬁcantly lower
in the HFD-Apo than the HFD-Con group (P<. 05, resp.)
(Figures 5(a)–5(c)). We further tested NF-κB activity in liver
nuclear extract samples from the mice of three experiment
groups. We found that signiﬁcantly less NF-κBa c t i v i t yw a s
derived from apocynin-treated mice than those derived from
untreated HFD-fed mice (P<. 05) (Figure 5(d)).
4. Discussion
Our present study indicates that apocynin administration
in HFD-fed C57BL/6 mice can improve insulin sensitivity,
reduce the diverse plasma inﬂammatory cytokines, suppress
gene expression of inﬂammation-related molecules in both
liver and adipose tissue, and decrease the activity of tran-
scription factor NF-κB in liver tissue. These results suggest
that apocynin could ameliorate insulin resistance through
the suppression of inﬂammation in HFD-fed C57BL/6 mice.Mediators of Inﬂammation 5
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Figure 3: Eﬀects of apocynin on the plasma inﬂammatory markers. (a) Plasma TNF-α levels. It was shown that apocynin decreased the level
of plasma TNF-α in HFD-Apo group compared to the HFD-Con group. (b) Plasma IL-6 levels. The plasma IL-6 level in HFD-Apo group is
lower than that in HFD-Con group. (c) Plasma leptin levels. Apocynin decreased the level of plasma leptin in HFD-Apo compared with the
HFD-Con group. #P<. 05 versus ND-Con group, ##P<. 01 versus ND-Con group, ∗P<. 05 versus HFD-Con group.
To reﬂect modern dietary conditions, we employed
C57BL/6 mice fed with HFD (60% kcal from fat) for 12
weeks which is a simple insulin resistance model. HFD-fed
mice exhibited higher body weight than normal diet mice.
Although food and energy intakes were not signiﬁcantly
diﬀerent, the body weight of the HFD-Con group was
increased,whereasthatoftheHFD-Apogroupwasdecreased
and close to ND-Con group. The HFD-fed mice exhibited
signiﬁcantly higher fasting glucose, fasting insulin levels,
and AUC of IPGTT than normal control mice. Apocynin
treatment dramatically decreased these indexes of insulin
resistance.
Apocynin is an antioxidant which can be used as an
inhibitor of NADPH oxidase. Recently, there have been
a few studies that implicated that apocynin may improve
insulin resistance which are consistent with the results of the
present study. Winiarska and colleagues found that apocynin
could inhibit renal gluconeogenesis action by suppressing
oxidative stress, resulting in hypoglycaemic response in
diabetic rabbits [32]. Another study indicated that apocynin
administration decreased lipid peroxidation and hydrogen
peroxide in adipose tissue which led to the improvement
of plasma glucose and insulin resistance in KKAy mice, a
transgenic animal model of type 2 diabetes [33]. Also, the
antioxidative eﬀect of apocynin was protective in diabetic
nephropathy [34, 35], in diabetic endothelial dysfunction
[36, 37], and in diabetic mitochondrial dysfunction in
skeletal muscle [38]. However, none of the previous studies
focused on the anti-inﬂammatory eﬀect of apocynin on
insulin resistance.
Inﬂammation has been deﬁned as an important contrib-
utor to insulin resistance in last century. Overproduction
of inﬂammatory factors can cause insulin resistance. In
contrast, suppressing inﬂammatory factors may ameliorate
insulin resistance [39, 40]. The molecular pathways that
link inﬂammation and insulin resistance include a variety
of cytokines and adipocytokines such as TNF-α,I L - 6 ,M C P -
1, leptin, and adiponectin [2]. High circulating levels of
TNF-α, IL-6, and leptin are recognized as markers of insulin
resistance [10, 41, 42].
The liver and adipose tissue are two major insulin action
organs. The inﬂammatory status of the liver and adipose
tissuecoulddirectlyimpactthesystemicinﬂammatorystatus
that accompanies insulin resistance. Inﬂammation-related6 Mediators of Inﬂammation
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Figure 4: Eﬀects of apocynin on inﬂammation-related genes expression in adipose tissue. The levels of mRNA expression of TNF-α,I L - 6 ,
MCP-1, leptin, and adiponectin in the epididymal adipose tissue were determined by quantitative PCR. (a) TNF-α,( b )I L - 6 ,( c )M C P - 1 ,
(d) Leptin, and (e) Adiponectin. Apocynin decreased the gene expression of TNF-α, IL-6, MCP-1, and leptin in HFD-Apo compared to the
HFD-Con group. The gene expression of adiponectin did not change among three groups. #P<. 05 versus ND-Con group, ∗P<. 05 versus
HFD-Con group.
transcription factor NF-κB in the liver is regarded as an
important factor for inducing insulin resistance. Increased
hepatic NF-κB activity could cause profound hepatic insulin
resistance and moderate systemic insulin resistance [8].
Furthermore, as a transcription factor, NF-κB regulates
expression of many kinds of cytokines in the liver. Once
NF-κB is activated, the gene expression of TNF-α,I L - 6 ,
and MCP-1 is inordinately increased [6, 7]. The endocrine
function of adipose tissue and the association of obesity
result in chronic low-grade inﬂammation and reinforce the
concept of the central role of adipose tissue in mediating
obesity-linked insulin resistance [43]. It has been discoveredMediators of Inﬂammation 7
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Figure 5: Eﬀectsofapocynin oninﬂammation-relatedgenes expressionandtheactivityofNF-κB intheliver. Apocynintreatment decreased
the gene expression of (a) TNF-α, (b) IL-6, (c) MCP-1 in HFD-Apo group compared to HFD-Con group. (d) Hepatic NF-κBa c t i v i t yw a s
tested by the special kit (Trans-AM NF-κB kit). The hepatic NF-κB activity is lower in the HFD-Apo group than that in the HFD-Con group.
that the adipose tissue in fact contributes 15–35% of the
body’s basal circulating IL-6 and a large rate of whole body
TNF-α [44]. Adipose tissue macrophages (ATMs) are proved
to be predominantly responsible for the elevated production
of TNF-α [45] and IL-6 during obesity [46]. MCP-1 could
contribute macrophage inﬁltration into adipose tissue and
aﬀect the number of ATMs in adipose tissue, which in turn
impacts the expression of TNF-α and IL-6. Moreover, leptin
is almost exclusively expressed in adipose tissue. So gene
expression of leptin in adipose tissue directly aﬀects leptin
level in the blood.
Apocynin is a traditional antioxidant. However, Hart
and his colleagues found that apocynin could reduce
inﬂammation as well as superoxide anion [47]. Afterwards,
a number of studies have demonstrated that apocynin
could modulate the production of inﬂammatory factors
production both in vitro [27–31]a n din vivo [25, 33, 48].
In the present study, we investigated the eﬀect of apocynin
on the inﬂammatory status through HFD-induced insulin
resistance in C57BL/6 mice. Our results show that the gene
expression of TNF-α, IL-6, and MCP-1 in the liver and
the gene expression of TNF-α, IL-6, MCP-1, and leptin in
adipose tissue were upregulated after HFD feeding in mice.
Apocynin administration suppressed the expression of these
inﬂammatoryagents,resultinginthereductionofcirculating
TNF-α, IL-6, and leptin levels that normally accompany
insulin resistance.
Furthermore, we found that apocynin could reduce
the activity of hepatic NF-κB which contributes to the
improvementofinsulinresistancebothintheliverandwhole
body. How can the antioxidant apocynin decrease the NF-κB
activity?Thereiscompellingevidencethatinmanycelltypes,
ROS such as hydrogen peroxide and superoxide anion have a
major eﬀect on the release and nuclear translocation of the
NF-κB complex and on the induction of NF-κBt a r g e tg e n e s
[49, 50]. NADPH oxidase, a major source of ROS, triggers
the production of superoxide anion [51, 52]. Hence, it is
reasonable that apocynin, an inhibitor of NADPH oxidase,
suppresses NF-κB activity. Our results are in agreement
with a study conducted by Pechanova and his colleagues
who used apocynin in spontaneously hypertensive rats. After
six weeks of treatment, apocynin signiﬁcantly decreased
the activity of NF-κB in the left ventricle [25]. Although
in the present study, we have proved that apocynin could
ameliorate inﬂammatory status and suppress the activity of
NF-κB in the liver, changes in other inﬂammatory signaling8 Mediators of Inﬂammation
pathways and insulin signaling remain unknown. Further
investigations will be conducted in our lab.
In conclusion, apocynin has the potential to improve
insulin sensitivity through ameliorating inﬂammatory status
in the blood, liver, and adipose tissue of the C57BL/6 mice
in which insulin resistance was induced by HFD. Hence,
apocynin is a promising agent for treating insulin resistance.
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